Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) End-Stage Kidney Disease Treatment Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global End-Stage Kidney Disease Treatment Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 MK-3866
      • 1.3.3 Pacritinib
      • 1.3.4 Sanguinate
      • 1.3.5 Tesidolumab
      • 1.3.6 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global End-Stage Kidney Disease Treatment Market Share by Application (2019-2025)
      • 1.4.2 Clinic
      • 1.4.3 Hospital
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global End-Stage Kidney Disease Treatment Market Size
      • 2.1.1 Global End-Stage Kidney Disease Treatment Revenue 2014-2025
      • 2.1.2 Global End-Stage Kidney Disease Treatment Sales 2014-2025
    • 2.2 End-Stage Kidney Disease Treatment Growth Rate by Regions
      • 2.2.1 Global End-Stage Kidney Disease Treatment Sales by Regions 2014-2019
      • 2.2.2 Global End-Stage Kidney Disease Treatment Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 End-Stage Kidney Disease Treatment Sales by Manufacturers
      • 3.1.1 End-Stage Kidney Disease Treatment Sales by Manufacturers 2014-2019
      • 3.1.2 End-Stage Kidney Disease Treatment Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 End-Stage Kidney Disease Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 End-Stage Kidney Disease Treatment Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global End-Stage Kidney Disease Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.3 End-Stage Kidney Disease Treatment Price by Manufacturers
    • 3.4 Key Manufacturers End-Stage Kidney Disease Treatment Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into End-Stage Kidney Disease Treatment Market
    • 3.6 Key Manufacturers End-Stage Kidney Disease Treatment Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 MK-3866 Sales and Revenue (2014-2019)
      • 4.1.2 Pacritinib Sales and Revenue (2014-2019)
      • 4.1.3 Sanguinate Sales and Revenue (2014-2019)
      • 4.1.4 Tesidolumab Sales and Revenue (2014-2019)
      • 4.1.5 Others Sales and Revenue (2014-2019)
    • 4.2 Global End-Stage Kidney Disease Treatment Sales Market Share by Type
    • 4.3 Global End-Stage Kidney Disease Treatment Revenue Market Share by Type
    • 4.4 End-Stage Kidney Disease Treatment Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global End-Stage Kidney Disease Treatment Sales by Application

    6 United States

    • 6.1 United States End-Stage Kidney Disease Treatment Breakdown Data by Company
    • 6.2 United States End-Stage Kidney Disease Treatment Breakdown Data by Type
    • 6.3 United States End-Stage Kidney Disease Treatment Breakdown Data by Application

    7 European Union

    • 7.1 European Union End-Stage Kidney Disease Treatment Breakdown Data by Company
    • 7.2 European Union End-Stage Kidney Disease Treatment Breakdown Data by Type
    • 7.3 European Union End-Stage Kidney Disease Treatment Breakdown Data by Application

    8 China

    • 8.1 China End-Stage Kidney Disease Treatment Breakdown Data by Company
    • 8.2 China End-Stage Kidney Disease Treatment Breakdown Data by Type
    • 8.3 China End-Stage Kidney Disease Treatment Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World End-Stage Kidney Disease Treatment Breakdown Data by Company
    • 9.2 Rest of World End-Stage Kidney Disease Treatment Breakdown Data by Type
    • 9.3 Rest of World End-Stage Kidney Disease Treatment Breakdown Data by Application
    • 9.4 Rest of World End-Stage Kidney Disease Treatment Breakdown Data by Countries
      • 9.4.1 Rest of World End-Stage Kidney Disease Treatment Sales by Countries
      • 9.4.2 Rest of World End-Stage Kidney Disease Treatment Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 BLR Bio LLC
      • 10.1.1 BLR Bio LLC Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of End-Stage Kidney Disease Treatment
      • 10.1.4 End-Stage Kidney Disease Treatment Product Introduction
      • 10.1.5 BLR Bio LLC Recent Development
    • 10.2 CTI BioPharma Corp
      • 10.2.1 CTI BioPharma Corp Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of End-Stage Kidney Disease Treatment
      • 10.2.4 End-Stage Kidney Disease Treatment Product Introduction
      • 10.2.5 CTI BioPharma Corp Recent Development
    • 10.3 F. Hoffmann-La Roche Ltd
      • 10.3.1 F. Hoffmann-La Roche Ltd Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of End-Stage Kidney Disease Treatment
      • 10.3.4 End-Stage Kidney Disease Treatment Product Introduction
      • 10.3.5 F. Hoffmann-La Roche Ltd Recent Development
    • 10.4 Novartis AG
      • 10.4.1 Novartis AG Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of End-Stage Kidney Disease Treatment
      • 10.4.4 End-Stage Kidney Disease Treatment Product Introduction
      • 10.4.5 Novartis AG Recent Development
    • 10.5 Prolong Pharmaceuticals LLC
      • 10.5.1 Prolong Pharmaceuticals LLC Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of End-Stage Kidney Disease Treatment
      • 10.5.4 End-Stage Kidney Disease Treatment Product Introduction
      • 10.5.5 Prolong Pharmaceuticals LLC Recent Development
    • 10.6 VESSL Therapeutics Ltd
      • 10.6.1 VESSL Therapeutics Ltd Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of End-Stage Kidney Disease Treatment
      • 10.6.4 End-Stage Kidney Disease Treatment Product Introduction
      • 10.6.5 VESSL Therapeutics Ltd Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 End-Stage Kidney Disease Treatment Sales Channels
      • 11.2.2 End-Stage Kidney Disease Treatment Distributors
    • 11.3 End-Stage Kidney Disease Treatment Customers

    12 Market Forecast

    • 12.1 Global End-Stage Kidney Disease Treatment Sales and Revenue Forecast 2019-2025
    • 12.2 Global End-Stage Kidney Disease Treatment Sales Forecast by Type
    • 12.3 Global End-Stage Kidney Disease Treatment Sales Forecast by Application
    • 12.4 End-Stage Kidney Disease Treatment Forecast by Regions
      • 12.4.1 Global End-Stage Kidney Disease Treatment Sales Forecast by Regions 2019-2025
      • 12.4.2 Global End-Stage Kidney Disease Treatment Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of End-Stage Kidney Disease Treatment is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for End-Stage Kidney Disease Treatment.

      This report studies the global market size of End-Stage Kidney Disease Treatment, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the End-Stage Kidney Disease Treatment sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      BLR Bio LLC
      CTI BioPharma Corp
      F. Hoffmann-La Roche Ltd
      Novartis AG
      Prolong Pharmaceuticals LLC
      VESSL Therapeutics Ltd
      ...

      Market Segment by Product Type
      MK-3866
      Pacritinib
      Sanguinate
      Tesidolumab
      Others

      Market Segment by Application
      Clinic
      Hospital
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the End-Stage Kidney Disease Treatment status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key End-Stage Kidney Disease Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of End-Stage Kidney Disease Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now